<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02458235</url>
  </required_header>
  <id_info>
    <nct_id>NCT02458235</nct_id>
  </id_info>
  <brief_title>Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation</brief_title>
  <official_title>A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether post-transplant consolidation with azacitidine
      combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the
      prevention of relapse in pediatric and young adult patients with hematologic malignancies who
      have undergone hematopoietic stem cell transplantation (HSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II single-arm trial of azacitidine (IV or SC) in combination with escalating
      donor lymphocyte infusion (DLI). Patients will be enrolled on the study by day +28 +/- 7
      post-transplant, prior to withdrawal of immunosuppression or administration of donor
      lymphocyte infusion (DLI). They will have donor chimerism and minimal residual disease (MRD)
      testing from peripheral blood (PB) and bone marrow (BM) on day +28 ± 7. Patients will be
      stratified according to risk categories (low, standard and high), defined by GVHD status,
      mixed versus full donor chimerism, and positive versus negative MRD results. Depending on
      risk assessment, immunosuppression will be tapered according to standard or fast schedules,
      and patients (with the exception of low-risk ALL patients) will receive one cycle of low-dose
      azacitidine (40mg/m2 IV/SC daily x 4 days). After tapering immunosuppression, chimerism will
      be repeated and patients will receive up to 6 additional cycles of low-dose azacitidine,
      depending on risk assessment. For patients who meet criteria for high risk of relapse,
      azacitidine will be combined with escalating doses of DLI for a maximum of 7 cycles in total.
      Risk and safety assessments, including routine laboratory parameters, donor chimerism,
      minimal residual disease, and GHVD activity will be assessed following each cycle. Chimerism
      and minimal residual disease testing will be repeated every cycle by peripheral blood (PB),
      and bone marrow (BM) will be tested every other cycle. Patients will be followed by
      laboratory monitoring and physician evaluation prior to each cycle, and will be followed for
      two years post-transplant to study toxicity and GVHD outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3 or higher adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>To be graded using CTCAE 4.0. Adverse events to be reported include renal, hepatic, cardiac, pulmonary, or neurologic toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute and chronic Graft versus Host Disease (GVHD)</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence will be reported for Grade 3-4 acute GVHD and moderate to severe chronic GVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to relapse</measure>
    <time_frame>2 years</time_frame>
    <description>To be measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transplant immune reconstitution</measure>
    <time_frame>2 years</time_frame>
    <description>Effect of azacitidine in combination with DLI on immune function as measured by flow cytometry and proliferation to mitogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD detection in patients with AML</measure>
    <time_frame>2 years</time_frame>
    <description>In addition to conventional flow cytometry, feasibility of gene expression profiling for detection of MRD in AML will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacitidine/donor lymphocyte infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals</description>
    <arm_group_label>Azacitidine/donor lymphocyte infusion</arm_group_label>
    <other_name>Vidaza®, Ladakamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>donor lymphocyte infusion</intervention_name>
    <description>For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.</description>
    <arm_group_label>Azacitidine/donor lymphocyte infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 0 - 29.9 years undergoing allogeneic peripheral blood stem cell
             transplant

          -  Patients with acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)

          -  Patients with juvenile myelomonocytic leukemia (JMML)

          -  Patients with myelodysplastic syndrome (MDS)

        Exclusion Criteria:

          -  Patients who have had a prior transplant.

          -  Patients with Fanconi anemia or other cancer-predisposition syndromes

          -  Patients with expected survival &lt;12 weeks

          -  Lansky score &lt;60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Willert, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014 Mar 6;123(10):1615-20. doi: 10.1182/blood-2013-10-535716. Epub 2014 Jan 16.</citation>
    <PMID>24435046</PMID>
  </reference>
  <reference>
    <citation>Tracey J, Zhang MJ, Thiel E, Sobocinski KA, Eapen M. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2013 Feb;19(2):255-9. doi: 10.1016/j.bbmt.2012.09.019. Epub 2012 Oct 3.</citation>
    <PMID>23041605</PMID>
  </reference>
  <reference>
    <citation>Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Révész T, Führer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM; European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005 Jan 1;105(1):410-9. Epub 2004 Sep 7.</citation>
    <PMID>15353481</PMID>
  </reference>
  <reference>
    <citation>Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, Einsele H, Niemeyer C, Benda N, Faul C, Kanz L, Niethammer D, Klingebiel T. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant. 1998 Mar;21(5):487-95.</citation>
    <PMID>9535041</PMID>
  </reference>
  <reference>
    <citation>Barrios M, Jiménez-Velasco A, Román-Gómez J, Madrigal ME, Castillejo JA, Torres A, Heiniger A. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003 Jul;88(7):801-10.</citation>
    <PMID>12857560</PMID>
  </reference>
  <reference>
    <citation>Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C, Einsele H, Schlegel PG, Niethammer D, Beck J, Klingebiel T. Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol. 2000 Mar;108(4):761-8.</citation>
    <PMID>10792281</PMID>
  </reference>
  <reference>
    <citation>Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, Tedone E, Frassoni F, Tong J, Marmont AM. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991 Apr 1;77(7):1423-8.</citation>
    <PMID>2009366</PMID>
  </reference>
  <reference>
    <citation>Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A, Messina C, Uderzo C, Ripaldi M, Porta F, Giorgiani G, Giraldi E, Pession A. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000 Mar 1;95(5):1572-9.</citation>
    <PMID>10688810</PMID>
  </reference>
  <reference>
    <citation>Storb R, Leisenring W, Anasetti C, Appelbaum FR, Deeg HJ, Doney K, Martin P, Sullivan KM, Witherspoon R, Pettinger M, Bensinger W, Buckner CD, Clift R, Flowers ME, Hansen JA, Pepe M, Chauncey T, Sanders J, Thomas ED. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant. 1997 Oct;3(4):194-201.</citation>
    <PMID>9360781</PMID>
  </reference>
  <reference>
    <citation>Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood. 1998 Nov 15;92(10):3582-90. Erratum in: Blood 1999 Mar 15;93(6):2141.</citation>
    <PMID>9808551</PMID>
  </reference>
  <reference>
    <citation>Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley JF, Goldman JM. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000 Jan 1;95(1):67-71.</citation>
    <PMID>10607686</PMID>
  </reference>
  <reference>
    <citation>Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant. 2008 Nov;42(9):569-79. doi: 10.1038/bmt.2008.259. Epub 2008 Aug 18. Review.</citation>
    <PMID>18711351</PMID>
  </reference>
  <reference>
    <citation>Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, Dörken B, Arnold R. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant. 2003 Mar;31(5):339-45.</citation>
    <PMID>12634724</PMID>
  </reference>
  <reference>
    <citation>Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002 Nov 1;100(9):3108-14.</citation>
    <PMID>12384406</PMID>
  </reference>
  <reference>
    <citation>Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet. 1984 Oct 13;2(8407):867-8.</citation>
    <PMID>6207398</PMID>
  </reference>
  <reference>
    <citation>Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother. 1999 Jan;22(1):16-24.</citation>
    <PMID>9924695</PMID>
  </reference>
  <reference>
    <citation>Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012 Apr 5;119(14):3361-9. doi: 10.1182/blood-2011-09-377044. Epub 2012 Jan 10.</citation>
    <PMID>22234690</PMID>
  </reference>
  <reference>
    <citation>Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007 Oct;31(10):1393-402. Epub 2007 Mar 27.</citation>
    <PMID>17391757</PMID>
  </reference>
  <reference>
    <citation>Gao XN, Lin J, Wang LL, Yu L. Demethylating treatment suppresses natural killer cell cytolytic activity. Mol Immunol. 2009 Jun;46(10):2064-70. doi: 10.1016/j.molimm.2009.02.033. Epub 2009 Apr 25.</citation>
    <PMID>19394699</PMID>
  </reference>
  <reference>
    <citation>Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011 Jun 15;128(12):2911-22. doi: 10.1002/ijc.25635. Epub 2010 Oct 19.</citation>
    <PMID>20960460</PMID>
  </reference>
  <reference>
    <citation>de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Dec 1;116(23):5420-31. doi: 10.1002/cncr.25500. Epub 2010 Jul 29.</citation>
    <PMID>20672358</PMID>
  </reference>
  <reference>
    <citation>Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2.</citation>
    <PMID>21886171</PMID>
  </reference>
  <reference>
    <citation>Klimek VM, Tallman MS. Hypomethylating agents in acute lymphoblastic leukemia: untapped potential? Leuk Lymphoma. 2011 Jan;52(1):7-8. doi: 10.3109/10428194.2010.524330. Epub 2010 Oct 7.</citation>
    <PMID>20929335</PMID>
  </reference>
  <reference>
    <citation>Yánez L, Bermúdez A, Richard C, Bureo E, Iriondo A. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia. 2009 Jul;23(7):1342-3. doi: 10.1038/leu.2009.58. Epub 2009 Mar 26.</citation>
    <PMID>19322208</PMID>
  </reference>
  <reference>
    <citation>Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.</citation>
    <PMID>23314834</PMID>
  </reference>
  <reference>
    <citation>Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun;27(12):1221-5.</citation>
    <PMID>11548839</PMID>
  </reference>
  <reference>
    <citation>Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1.</citation>
    <PMID>16882708</PMID>
  </reference>
  <reference>
    <citation>Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood. 1973 Sep;42(3):359-65.</citation>
    <PMID>4125239</PMID>
  </reference>
  <reference>
    <citation>Kalwinsky D, Mirro J Jr, Schell M, Behm F, Mason C, Dahl GV. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol. 1988 Jul;6(7):1134-43.</citation>
    <PMID>3292713</PMID>
  </reference>
  <reference>
    <citation>Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, Mahoney D, Weinstein H. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1996 May;14(5):1521-5.</citation>
    <PMID>8622066</PMID>
  </reference>
  <reference>
    <citation>Zetterquist H, Mattsson J, Uzunel M, Näsman-Björk I, Svenberg P, Tammik L, Bayat G, Winiarski J, Ringdén O. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2000 Apr;25(8):843-51.</citation>
    <PMID>10808205</PMID>
  </reference>
  <reference>
    <citation>Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia. 2001 Dec;15(12):1976-85.</citation>
    <PMID>11753621</PMID>
  </reference>
  <reference>
    <citation>Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M, Pelle-Day G, Cooperstein E, Baxter-Lowe LA. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant. 2009 Mar;43(6):469-76. doi: 10.1038/bmt.2008.339. Epub 2008 Oct 27.</citation>
    <PMID>18955982</PMID>
  </reference>
  <reference>
    <citation>Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25. Review.</citation>
    <PMID>23799371</PMID>
  </reference>
  <reference>
    <citation>Appelbaum FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol. 2013 Sep;26(3):279-84. doi: 10.1016/j.beha.2013.10.008. Epub 2013 Oct 16. Review.</citation>
    <PMID>24309531</PMID>
  </reference>
  <reference>
    <citation>Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program. 2012;2012:35-42. doi: 10.1182/asheducation-2012.1.35. Review.</citation>
    <PMID>23233558</PMID>
  </reference>
  <reference>
    <citation>Hourigan CS, McCarthy P, de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2):154-63. doi: 10.1016/j.bbmt.2013.11.017. Epub 2013 Nov 27. Review.</citation>
    <PMID>24291784</PMID>
  </reference>
  <reference>
    <citation>Bicigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola A, di Grazia C, Dominietto A, Romagnani C, Occhini D, Frassoni F, van Lint MT. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood. 2001 Nov 15;98(10):3174-5.</citation>
    <PMID>11721685</PMID>
  </reference>
  <reference>
    <citation>Ouachee-Chardin M, Dvorak C, Wahlstrom J, Cowan M, Facchino J, Horn B. Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory Therapy After Allogeneic Hematopoietic Stem Cell (HSCT) For Acute Leukemia. American Society of Hematology: Abstract. New Orleans, LA, 2013.</citation>
  </reference>
  <reference>
    <citation>Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec;19(12):1713-8. doi: 10.1016/j.bbmt.2013.09.011. Epub 2013 Sep 27.</citation>
    <PMID>24076323</PMID>
  </reference>
  <reference>
    <citation>Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Oelschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M. Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation. Blood Cancer J. 2013 Aug 30;3:e136. doi: 10.1038/bcj.2013.35.</citation>
    <PMID>23995045</PMID>
  </reference>
  <reference>
    <citation>Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, Conter V, Biondi A, Cazzaniga G, Valsecchi MG. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014 Feb;164(3):396-408. doi: 10.1111/bjh.12639.</citation>
    <PMID>24422724</PMID>
  </reference>
  <reference>
    <citation>Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013 Sep 5;122(10):1813-21. doi: 10.1182/blood-2013-06-506725. Epub 2013 Jul 11.</citation>
    <PMID>23847197</PMID>
  </reference>
  <reference>
    <citation>Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poirée M, Bordigoni P. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol. Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30.</citation>
    <PMID>24479958</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2015</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric leukemia myelodysplastic syndrome azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

